First-line combined Checkpoint Blockade in Patents with MSI-H/dMMR mCRC

被引：0
|
作者：
Klein, Friederike
机构：
来源：
ZEITSCHRIFT FUR GASTROENTEROLOGIE | 2022年 / 60卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：562 / 562
页数：1
相关论文
共 50 条
  • [41] ONCOLOGISTS' PERCEPTIONS OF NIVOLUMAB PLUS IPILUMUMAB (NIVO plus IPI) AS FIRST-LINE (1L) TREATMENT FOR MICROSATELLITE INSTABILITY-HIGH/MISMATCH REPAIR-DEFICIENT (MSI-H/DMMR) METASTATIC COLORECTAL CANCER (MCRC)
    Emidio, O.
    Iqbal, Z.
    Jeune-Smith, Y.
    Feinberg, B.
    VALUE IN HEALTH, 2024, 27 (12) : S351 - S351
  • [42] Endometrial Tumors with MSI-H and dMMR Share a Similar Tumor Immune Microenvironment
    Song, Yunfeng
    Gu, Ye
    Hu, Xiang
    Wang, Mengfei
    He, Qizhi
    Li, Yiran
    ONCOTARGETS AND THERAPY, 2021, 14 : 4485 - 4497
  • [43] Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer
    Inamori, Koji
    Togashi, Yosuke
    Fukuoka, Shota
    Akagi, Kiwamu
    Ogasawara, Kouetsu
    Irie, Takuma
    Motooka, Daisuke
    Kobayashi, Yoichi
    Sugiyama, Daisuke
    Kojima, Motohiro
    Shiiya, Norihiko
    Nakamura, Shota
    Maruyama, Shoichi
    Suzuki, Yutaka
    Ito, Masaaki
    Nishikawa, Hiroyoshi
    JCI INSIGHT, 2021, 6 (09)
  • [44] Tumor-agnostic drug development in dMMR/MSI-H solid tumors
    Bhamidipati, Deepak
    Subbiah, Vivek
    TRENDS IN CANCER, 2023, 9 (10): : 828 - 839
  • [45] PD-1 inhibition in metastatic dMMR/MSI-H colorectal cancer
    Sclafani, Francesco
    LANCET ONCOLOGY, 2017, 18 (09): : 1141 - 1142
  • [46] Immune checkpoint inhibitors in luminal gastrointestinal malignancies: going beyond MSI-H/dMMR, TMB and PD-L1
    Lefler, Daniel S.
    Snook, Adam E.
    Bashir, Babar
    IMMUNOTHERAPY, 2022, 14 (11) : 885 - 902
  • [47] Long-term survivals of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy in dMMR/MSI-H colorectal and gastric cancers
    Wang, Zhenghang
    Cheng, Siyuan
    Yao, Yanhong
    Liu, Shengde
    Liu, Zimin
    Liu, Ning
    Jin, Yongdong
    Zhang, Yinjie
    Yin, Fei
    Han, Guangjie
    Zhang, Jingdong
    Wang, Qiwei
    Yan, Dong
    Wang, Li
    Lu, Hongxia
    Deng, Ting
    Ji, Zhi
    Gao, Hui
    Fang, Weijia
    Zhang, Hangyu
    Chen, Zhiyu
    Zou, Jianling
    Tang, Yong
    Xu, Chunlei
    Li, Jiayi
    Qu, Huajun
    Bao, Liying
    Cao, Baoshan
    Wang, Xicheng
    Xu, Ting
    Sun, Yu
    Shen, Lin
    Peng, Zhi
    Li, Jian
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (09)
  • [48] Non-operative management after immune checkpoint inhibitors for early-stage, dMMR/MSI-H gastrointestinal cancers
    Fazio, Roberta
    Audisio, Alessandro
    Dapra, Valentina
    Conti, Chiara
    Benhima, Nada
    Abbassi, Fatima-Zahara
    Assaf, Irene
    Hendlisz, Alain
    Sclafani, Francesco
    CANCER TREATMENT REVIEWS, 2024, 128
  • [49] Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer
    Mazzoli, Giacomo
    Cohen, Romain
    Lonardi, Sara
    Corti, Francesca
    Elez, Elena
    Fakih, Marwan
    Jayachandran, Priya
    Colle, Raphael
    Shah, Aakash Tushar
    Salati, Massimiliano
    Fenocchio, Elisabetta
    Salvatore, Lisa
    Ambrosini, Margherita
    Ros, Javier
    Intini, Rossana
    Cremolini, Chiara
    Overman, Michael J.
    Andre, Thierry
    Pietrantonio, Filippo
    EUROPEAN JOURNAL OF CANCER, 2022, 172 : 171 - 181
  • [50] Prevalence and Associations of Beta2-Microglobulin Mutations in MSI-H/dMMR Cancers
    Liu, Fangcen
    Zhong, Fangfang
    Wu, Huan
    Che, Keying
    Shi, Jiaochun
    Wu, Nandie
    Fu, Yao
    Wang, Yue
    Hu, Jing
    Qian, Xiaoping
    Fan, Xiangshan
    Wang, Weifeng
    Wei, Jia
    ONCOLOGIST, 2023, : e136 - e144
12345